Australian Government
Department of Health, Disability and Ageing

Australian Technical Advisory Group on Immunisation (ATAGI)

Summary of the 125th meeting, 14 October 2026

Respiratory syncytial virus (RSV)

- ATAGI reviewed data on RSV disease in adults with medical conditions that increase their risk of severe RSV disease. This review will inform updates in early 2027 to ATAGI's advice on RSV vaccination in adults, including in the Australian Immunisation Handbook
- ATAGI reviewed draft advice on RSV – specific monoclonal antibody administration for Aboriginal and Torres Strait Islander infants and children. The advice is available on the department's website.

Influenza

- ATAGI held a focus session on FluMist live attenuated influenza vaccine (nasal spray). FluMist was available for the first time in 2026 through some state and territory funded programs or by private prescription for children aged 2 to 17 years.
- ATAGI reviewed and discussed the results of a survey study on parental attitudes towards influenza vaccination and parent and provider experiences with FluMist, as well as modelling data from the UK Health Security Agency.

Hepatitis B

- ATAGI reviewed and discussed a systematic review on immunisation options for people who do not respond to primary hepatitis B vaccination. The review will inform potential updates to ATAGI recommendations for hepatitis B non-responders in the Handbook.

ATAGI publications

- ATAGI is preparing a statement to address concerns about counterfeit rabies vaccines that are in circulation in the Philippines and other countries, and provide advice to travellers and healthcare providers. The statement is available on the department's website.

Departmental updates

- ATAGI received an update from the Therapeutic Goods Administration on vaccines that are currently under evaluation for registration in Australia.

Resources

- ATAGI's membership, terms of reference and declaration of interest information is available on the Department of Health, Disability and Ageing website.